Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Tvardi Therapeutics, Inc. has been given an average consensus rating of "Buy" from four brokerages, with a price target ranging from $52.00 to $78.00.
• The stock has experienced significant trading activity, reaching a current price of $40.23, with a twelve-month range between $8.13 and $41.00.
• In its latest earnings report, Tvardi Therapeutics reported a loss of ($1.00) earnings per share, which was below analysts' expectations of ($0.51).

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Get Free Report) have been assigned an average rating of "Buy" from the four ratings firms that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $64.25.

A number of equities research analysts have issued reports on the company. Raymond James Financial started coverage on Tvardi Therapeutics in a research report on Monday, July 14th. They issued an "outperform" rating and a $62.00 price target on the stock. Piper Sandler initiated coverage on Tvardi Therapeutics in a research report on Thursday, June 12th. They set an "overweight" rating and a $78.00 price target on the stock. Weiss Ratings reaffirmed a "sell (e)" rating on shares of Tvardi Therapeutics in a research report on Saturday, September 27th. Finally, Cantor Fitzgerald initiated coverage on Tvardi Therapeutics in a research report on Friday, July 11th. They set an "overweight" rating and a $52.00 price target on the stock.

Tvardi Therapeutics Stock Performance

NASDAQ TVRD traded up $2.86 during mid-day trading on Friday, hitting $40.23. The stock had a trading volume of 58,178 shares, compared to its average volume of 36,370. Tvardi Therapeutics has a twelve month low of $8.13 and a twelve month high of $41.00. The stock's 50 day moving average is $30.23.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative return on equity of 565.83% and a negative net margin of 678.79%.

Institutional Investors Weigh In On Tvardi Therapeutics

Several hedge funds have recently modified their holdings of TVRD. JPMorgan Chase & Co. acquired a new stake in shares of Tvardi Therapeutics during the second quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $43,000. Headlands Technologies LLC purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $80,000. New York State Common Retirement Fund purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $92,000. Finally, Bank of America Corp DE purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $399,000. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.